{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:16:02Z","timestamp":1786119362465,"version":"build-2736575974"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1097\/rlu.0b013e3181b7d6f4","type":"journal-article","created":{"date-parts":[[2009,10,17]],"date-time":"2009-10-17T03:17:50Z","timestamp":1255749470000},"page":"793-794","source":"Crossref","is-referenced-by-count":3,"title":["Histological Transformation of Follicular Lymphoma After Treatment"],"prefix":"10.1097","volume":"34","author":[{"given":"Luisa Maria","family":"Mena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Setoain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau","family":"Abrisqueta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"L\u00f3pez-Guillermo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Lafuente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Fuertes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastia","family":"Rub\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Pons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210204","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/MNM.0b013e3280895e23","article-title":"The role of FDG PET in the management of lymphoma: what is the evidence base?","volume":"28","author":"Kirby","year":"2007","journal-title":"Nucl Med Commun"},{"key":"R2-13-20210204","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1157\/13112510","article-title":"The value of positron emission tomography\/computed tomography (PET\/CT) in the staging of diffuse large B-cell lymphoma.","volume":"129","author":"Fuertes","year":"2007","journal-title":"Med Clin (Barc)"},{"key":"R3-13-20210204","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1089\/cbr.2005.20.185","article-title":"Yttrium-90 (90Y) Ibritumomab Tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-cell non-Hodgkin\u2032s lymphoma.","volume":"20","author":"Wiseman","year":"2005","journal-title":"Cancer Biother Radiopharm"},{"key":"R4-13-20210204","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/annonc\/mdi148","article-title":"Report of a European consensus workshop to develop recommendations for the optimal use of 90Y-ibritumomab tiuxetan (Zevalin) in lymphoma.","volume":"16","author":"Hagenbeek","year":"2005","journal-title":"Ann Oncol"},{"key":"R5-13-20210204","first-page":"267","article-title":"Administration guidelines for radioimmunotherapy of non-Hodgkin\u2032s lymphoma with 90Y-labeled anti-CD20 monoclonal antibody.","volume":"43","author":"Wagner","year":"2002","journal-title":"J Nucl Med"},{"key":"R6-13-20210204","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/asheducation-2006.1.259","article-title":"Utility of positron emission tomography (PET) scanning in managing patients with Hodgkin lymphoma.","volume":"2006","author":"Juweid","year":"2006","journal-title":"Hematology"},{"key":"R7-13-20210204","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/01.rlu.0000170086.45627.99","article-title":"FDG PET CT assessment of treatment response after yttrium-90 ibritumomab tiuxetan radioimmunotherapy.","volume":"30","author":"Joyce","year":"2005","journal-title":"Clin Nucl Med"},{"key":"R8-13-20210204","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1053\/j.seminoncol.2003.10.007","article-title":"Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin\u2032s lymphoma.","volume":"30","author":"Witzig","year":"2003","journal-title":"Semin Oncol"},{"key":"R9-13-20210204","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood-2007-01-068056","article-title":"Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation.","volume":"110","author":"Morschhauser","year":"2007","journal-title":"Blood"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00003072-200911000-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:07:13Z","timestamp":1786039633000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00003072-200911000-00013"}},"subtitle":["A Case Evaluated With PET\/CT"],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":9,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0b013e3181b7d6f4","relation":{},"ISSN":["0363-9762"],"issn-type":[{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}